If you have high cholesterol, there's a good chance your doctor has recommended statins to get your numbers back into a ...

This year’s top asthma and respiratory disorder story focused on the pushback from multiple advocacy groups following ...

The global home medical equipment market size US$ 29.1 billion in 2021. The global home medical equipment market is forecast to grow to US$ 43.9 billion by 2030 by growing at a compound annual growth ...

Dear Dr. Roach: In a recent column, you noted that many patients do not properly use their inhaled asthma/chronic obstructive pulmonary disease (COPD) medications, but you didn't tell us how to ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupix ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly ...

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

The FDA has approved Exdensur for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients aged 12 and older.

Allied Market Research published a report, titled, 'Respiratory Inhaler Devices Market by Product (Metered Dose Inhalers, Dry ...

Asthma care continues to develop, particularly in how treatment and long-term management are approached. This article outlines current treatment and management recommendations for patients aged 12 and ...

A monthly injection could enable severe asthma patients to stop taking daily steroid tablets without affecting their symptoms, a new trial has found. The drug, Tezepelumab (also known as Tezspir and ...